◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ANAB

AnaptysBio Inc (ANAB) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-14

AnaptysBio Inc (ANAB) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 104 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ANAB reported $235M in revenue and ($13M) in net income.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Interactive charts & full statements → Open the ANAB valuation workbench →

ANAB Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$232M	$235M	$91M	$17M	$10M	$63M	$75M	$8M	$5M	$10M	$17M	$18M	$16M	$5M
Gross Profit	$271M	$232M	($73M)	($115M)	($79M)	($35M)	($5M)	($91M)	($51M)	($19M)	$1M	$0M	$7M	($3M)
Gross Margin %	116.4%	99.0%	-79.5%	-671.0%	-763.2%	-55.9%	-6.7%	-1141.7%	-1023.9%	-194.4%	7.6%	1.5%	45.6%	-60.9%
Operating Income (EBIT)	$41M	$48M	($115M)	($164M)	($115M)	($57M)	($24M)	($107M)	($67M)	($29M)	($3M)	($3M)	$5M	($5M)
Operating Margin %	17.6%	20.4%	-125.9%	-958.3%	-1119.4%	-89.9%	-31.8%	-1342.9%	-1334.4%	-287.8%	-18.1%	-18.9%	30.8%	-96.4%
Net Income	($27M)	($13M)	($145M)	($164M)	($129M)	($58M)	($20M)	($97M)	($62M)	($30M)	($4M)	($5M)	$0M	($6M)
Net Margin %	-11.5%	-5.6%	-159.1%	-953.7%	-1251.3%	-91.5%	-26.6%	-1216.7%	-1233.1%	-300.7%	-25.5%	-30.8%	1.5%	-101.1%
EBITDA	$58M	$69M	($93M)	($156M)	($105M)	($56M)	($19M)	($96M)	($60M)	($28M)	($4M)	($5M)	$5M	($4M)
Earnings Per Share (EPS)	$-1.08	$-0.42	$-5.12	$-6.08	$-4.57	$-2.11	$-0.73	$-3.60	$-2.50	$-1.52	$-1.62	$-2.12	$0.09	$-4.98
Shares Outstanding (M)	29M	31M	28M	27M	28M	27M	27M	27M	25M	20M	3M	3M	2M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANAB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$26M	$108M	$76M	$22M	$28M	$43M	$30M	$11M
Gross Profit	$25M	$216M	$45M	($16M)	($13M)	$1M	($12M)	($31M)
Gross Margin %	97.6%	199.8%	58.9%	-69.9%	-48.3%	1.2%	-40.6%	-282.8%
Operating Income (EBIT)	($35M)	$67M	$35M	($26M)	($28M)	($10M)	($23M)	($40M)
Operating Margin %	-135.5%	61.8%	45.5%	-117.5%	-99.2%	-22.4%	-75.8%	-367.5%
Net Income	($53M)	$50M	$15M	($39M)	($39M)	($22M)	($33M)	($47M)
Net Margin %	-206.9%	45.8%	19.8%	-173.5%	-141.6%	-50.5%	-109.4%	-425.3%
EBITDA	($31M)	$70M	$38M	($18M)	($21M)	($4M)	($17M)	($35M)
Earnings Per Share (EPS)	$-1.84	$1.58	$0.52	$-1.34	$-1.28	$-0.72	$-1.14	$-1.71
Shares Outstanding (M)	29M	31M	29M	29M	31M	30M	29M	27M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANAB Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	$4M	$20M	($135M)	($121M)	($74M)	($46M)	($14M)	($70M)	($49M)	($19M)	($9M)	($10M)	$15M	($6M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$1M	$0M	$1M	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$4M	$20M	($136M)	($122M)	($74M)	($47M)	($15M)	($70M)	($50M)	($20M)	($9M)	($10M)	$14M	($6M)
FCF Margin %	1.9%	8.4%	-148.7%	-708.8%	-718.9%	-74.9%	-19.6%	-879.0%	-991.4%	-197.3%	-54.4%	-56.4%	91.3%	-106.4%
Dividends Paid	—	—	—	$12M	—	—	—	—	—	$0M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANAB Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	($26M)	$98M	($27M)	($40M)	($11M)	($67M)	($10M)	($21M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($26M)	$98M	($27M)	($40M)	($11M)	($67M)	($10M)	($21M)
FCF Margin %	-101.5%	90.5%	-35.9%	-180.9%	-38.7%	-155.2%	-33.7%	-194.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANAB Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$330M	$364M	$484M	$452M	$610M	$643M	$417M	$435M	$509M	$329M	$62M	$56M	$25M	$4M
Cash & Cash Equivalents	$248M	$238M	$123M	$36M	$71M	$496M	$250M	$171M	$114M	$81M	$51M	$52M	$22M	$3M
Total Liabilities	$317M	$327M	$413M	$364M	$348M	$287M	$20M	$30M	$23M	$22M	$23M	$14M	$19M	$4M
Total Debt (Short + Long-Term)	$2M	$2M	$2M	$2M	$2M	$2M	$0M	$2M	$8M	$14M	$14M	$5M	$5M	$1M
Total Shareholders' Equity	$13M	$37M	$71M	$88M	$262M	$356M	$397M	$405M	$486M	$308M	$39M	$42M	$6M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANAB viewer.

Other Companies in BIOTECHNOLOGY

NVAX · Novavax Inc — $2 billion
KLRA · Kailera Therapeutics, Inc. Common Stock — $2 billion
ABSI · Absci Corp — $2 billion
TSHA · Taysha Gene Therapies Inc — $2 billion
INBX · Inhibrx Biosciences, Inc. — $2 billion
SNDX · Syndax Pharmaceuticals Inc — $2 billion
KARD · Kardigan, Inc. Common Stock — $2 billion
INVA · Innoviva Inc — $2 billion

← AN All “A” companies ANAN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.